Logo image of MGNX

MACROGENICS INC (MGNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MGNX - US5560991094 - Common Stock

1.635 USD
+0.14 (+9%)
Last: 12/22/2025, 1:10:05 PM
Fundamental Rating

3

MGNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. MGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MGNX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MGNX had negative earnings in the past year.
MGNX had a negative operating cash flow in the past year.
In the past 5 years MGNX always reported negative net income.
In the past 5 years MGNX always reported negative operating cash flow.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of MGNX (-28.03%) is better than 68.87% of its industry peers.
With a Return On Equity value of -113.26%, MGNX perfoms like the industry average, outperforming 42.83% of the companies in the same industry.
Industry RankSector Rank
ROA -28.03%
ROE -113.26%
ROIC N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 75.41%, MGNX belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.
MGNX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

6

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MGNX has more shares outstanding
Compared to 5 years ago, MGNX has more shares outstanding
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.16, we must say that MGNX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.16, MGNX is not doing good in the industry: 65.09% of the companies in the same industry are doing better.
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.16
ROIC/WACCN/A
WACC8.8%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

MGNX has a Current Ratio of 5.22. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.22, MGNX is in line with its industry, outperforming 57.74% of the companies in the same industry.
MGNX has a Quick Ratio of 5.02. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.02, MGNX is in line with its industry, outperforming 57.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 5.02
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

MGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.05%, which is quite impressive.
MGNX shows a decrease in Revenue. In the last year, the revenue decreased by -9.70%.
Measured over the past years, MGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.49% on average per year.
EPS 1Y (TTM)24.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
Revenue 1Y (TTM)-9.7%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%-34.21%

3.2 Future

The Earnings Per Share is expected to decrease by -4.98% on average over the next years.
Based on estimates for the next years, MGNX will show a very negative growth in Revenue. The Revenue will decrease by -12.53% on average per year.
EPS Next Y-14.09%
EPS Next 2Y-31.47%
EPS Next 3Y-25.51%
EPS Next 5Y-4.98%
Revenue Next Year-23.4%
Revenue Next 2Y-38.58%
Revenue Next 3Y-27.41%
Revenue Next 5Y-12.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

MGNX's earnings are expected to decrease with -25.51% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.47%
EPS Next 3Y-25.51%

More info and screens

0

5. Dividend

5.1 Amount

MGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MACROGENICS INC

NASDAQ:MGNX (12/22/2025, 1:10:05 PM)

1.635

+0.14 (+9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners69.03%
Inst Owner Change-4.9%
Ins Owners1.03%
Ins Owner Change1.31%
Market Cap103.43M
Revenue(TTM)127.63M
Net Income(TTM)-75.89M
Analysts75.38
Price Target3.47 (112.23%)
Short Float %6.22%
Short Ratio3.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)80.96%
Min EPS beat(2)8.09%
Max EPS beat(2)153.84%
EPS beat(4)4
Avg EPS beat(4)56.06%
Min EPS beat(4)8.09%
Max EPS beat(4)153.84%
EPS beat(8)5
Avg EPS beat(8)10.71%
EPS beat(12)7
Avg EPS beat(12)26.04%
EPS beat(16)8
Avg EPS beat(16)19.11%
Revenue beat(2)2
Avg Revenue beat(2)284.48%
Min Revenue beat(2)183.18%
Max Revenue beat(2)385.79%
Revenue beat(4)3
Avg Revenue beat(4)159.13%
Min Revenue beat(4)-42.16%
Max Revenue beat(4)385.79%
Revenue beat(8)4
Avg Revenue beat(8)65.32%
Revenue beat(12)5
Avg Revenue beat(12)28.03%
Revenue beat(16)7
Avg Revenue beat(16)22.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.35%
EPS NY rev (1m)39.42%
EPS NY rev (3m)39.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)20.65%
Revenue NY rev (1m)78.76%
Revenue NY rev (3m)78.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS2.02
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.03%
ROE -113.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.41%
FCFM N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.45%
Cap/Sales 1.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.22
Quick Ratio 5.02
Altman-Z -6.16
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)32.65%
Cap/Depr(5y)40.48%
Cap/Sales(3y)2.62%
Cap/Sales(5y)4.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
EPS Next Y-14.09%
EPS Next 2Y-31.47%
EPS Next 3Y-25.51%
EPS Next 5Y-4.98%
Revenue 1Y (TTM)-9.7%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%-34.21%
Revenue Next Year-23.4%
Revenue Next 2Y-38.58%
Revenue Next 3Y-27.41%
Revenue Next 5Y-12.53%
EBIT growth 1Y-6.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.91%
EBIT Next 3Y-14.91%
EBIT Next 5YN/A
FCF growth 1Y-636.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-679.22%
OCF growth 3YN/A
OCF growth 5YN/A

MACROGENICS INC / MGNX FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGNX.


What is the valuation status for MGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.


What is the profitability of MGNX stock?

MACROGENICS INC (MGNX) has a profitability rating of 2 / 10.